Diabetic Nephropathy Pathophysiology and Management

Diabetic nephropathy arises from sustained hyperglycaemia, haemodynamic alterations and metabolic stress that converge on the glomerular microvasculature. Persistent high glucose levels promote thickening of the glomerular basement membrane, mesangial expansion and podocyte injury, leading to albuminuria and progressive loss of filtration capacity. Inflammation and oxidative stress, driven by advanced glycation end products and activation of the renin–angiotensin–aldosterone system, accelerate tubular fibrosis and reduce nephron number. Clinically this manifests as a continuum from microalbuminuria through overt proteinuria to a decline in estimated glomerular filtration rate and, ultimately, end-stage renal disease. Management strategies centre on tight glycaemic control, blockade of the renin–angiotensin–aldosterone axis and contemporary use of sodium–glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists to slow progression. Attention to comorbidities such as anaemia and hypertension, along with personalised risk assessment by histopathology and biomarkers, is reshaping therapeutic paradigms towards precision care and improved patient outcomes.

Research from Nature Portfolio

Recent studies have demonstrated that inappropriately low erythropoietin levels in anaemic diabetic patients predict a more rapid decline in glomerular filtration rate, highlighting a link between early hormonal deficiency and renal prognosis. In parallel, single-glomerulus proteomic analysis has identified a distinct lesion—solidified glomerulosclerosis—strongly associated with progression to end-stage renal disease. This work revealed overexpression of complement components and lipid-handling proteins within the affected glomeruli, offering novel molecular targets for intervention.

Diabetic Nephropathy Pathophysiology and Management publication trend

The graph below shows the total number of articles in diabetic nephropathy pathophysiology and management across all publications each year (not limited to Nature Index journals).

Technical terms

Podocyte: Specialized epithelial cell that wraps around the glomerular capillaries and maintains the filtration barrier.

Glomerular basement membrane (GBM): Thin extracellular matrix between endothelial cells and podocytes, crucial for selective filtration.

Albuminuria: Presence of albumin in urine, an early marker of glomerular injury.

Estimated glomerular filtration rate (eGFR): Calculated measure of kidney filtration function based on serum creatinine and demographic variables.

Sodium–glucose cotransporter 2 (SGLT2) inhibitor: Class of antidiabetic agent that reduces hyperglycaemia and exerts renoprotective effects.

End-stage renal disease (ESRD): Final stage of chronic kidney disease requiring dialysis or transplantation.

References

1. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Scientific Reports (2019).
2. Solidified glomerulosclerosis, identified using single glomerular proteomics, predicts end-stage renal disease in Chinese patients with type 2 diabetes. Scientific Reports (2021).
3. Artificial intelligence assists identification and pathologic classification of glomerular lesions in patients with diabetic nephropathy. Journal of Translational Medicine (2024).
4. Comparative analysis of four nutritional scores in predicting adverse outcomes in biopsy-confirmed diabetic kidney Disease. Frontiers in Nutrition (2024).
5. Should we enlarge the indication for kidney biopsy in patients with diabetes? The pro part. Clinical Kidney Journal (2023).